Skip to main content
. 2025 Jan 13;40(1):11. doi: 10.1007/s00384-024-04798-2

Fig. 3.

Fig. 3

Overall survival for patients stratified by the presence or absence of CIN of any grade during cycles 1 and 2, adjusted for age, sex, combination with bevacizumab, time since diagnosis of metastasis until commencement of FTD/TPI < 18 months, and number of metastatic organs ≥ 3. The shaded area indicates the upper and lower boundaries of the 95% confidence interval